SNB 011
Alternative Names: Airnecflu®; Pentarlandir™; Pentarlandir™ Ultrapure and Potent Tannic Acid; Pentarlandir™ UPPTA; SNB-01; SNB-011Latest Information Update: 28 Jul 2025
At a glance
- Originator SyneuRx International (Taiwan) corp
- Class Anti-inflammatories; Antivirals; Biopolymers; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors; Cytokine inhibitors; D amino acid oxidase inhibitors; Serine protease inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II COVID 2019 infections
- Preclinical Influenza virus infections
- No development reported Anxiety disorders; Depressive disorders; Memory disorders
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Anxiety-disorders in Taiwan (PO, Capsule)
- 28 Jul 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in Taiwan (PO, Capsule)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Depressive disorders in Taiwan (PO, Capsule)